Core Points - The company, Hebang Biotechnology (603077.SH), announced the need to pay a total of 71.474 million yuan in corporate income tax and late fees for the period from January 1, 2023, to December 31, 2023 [1] - As of the date of the announcement, the company has completed the payment of the aforementioned tax and late fees, and this matter does not involve any administrative penalties [1] - The payment of the tax and late fees will be recorded in the company's profit and loss for the year 2025, and it is expected to impact the net profit attributable to shareholders of the listed company by 71.474 million yuan, subject to the final audited financial statements for 2025 [1]

| 证券代码：603077 | 证券简称：和邦生物 | 公告编号：2025-043 | | --- | --- | --- | | 债券代码：113691 | 债券简称：和邦转债 | | 四川和邦生物科技股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 09 月 15 日（星期一）至 09 月 19 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 jsy@hebang.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 四川和邦生物科技股份有限公司（以下简称"公司"）已于 2025 年 8 月 20 日发布《四川和邦生物科技股份有限公司 2025 年半年度报告》，为便于广大投资 者更全面深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 09 月 22 日（星期一）16:00-17:00 举行 2025 年半年度业绩说明会，就投资 者关心的问题进 ...

证券代码：603077 证券简称：和邦生物 公告编号：2025-042 债券代码：113691 债券简称：和邦转债 四川和邦生物科技股份有限公司 关于公司补缴税款的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、对公司的影响 根据《企业会计准则第 28 号--会计政策、会计估计变更和差错更正》相关 规定，上述补缴税款及滞纳金事项不属于前期会计差错，不涉及前期财务数据追 溯调整。公司补缴上述税款及滞纳金将计入 2025 年当期损益，预计将影响公司 2025 年度归属于上市公司股东的净利润 71,473,969.37 元，最终以 2025 年度经 审计的财务报表为准。 特此公告。 四川和邦生物科技股份有限公司董事会 2025 年 9 月 12 日 四川和邦生物科技股份有限公司（以下简称"公司"）根据税法相关规定对 涉税业务开展了自查，现将有关情况公告如下： 一、基本情况 经自查，公司需补缴 2023 年 1 月 1 日至 2023 年 12 月 31 日企业所得税及滞 纳金合计 71,473,969.37 元。截至本公告 ...

Group 1 - The company, Hebang Biology (603077.SH), announced that it needs to pay a total of 71.474 million yuan in corporate income tax and late fees for the period from January 1, 2023, to December 31, 2023 [1] - As of the date of the announcement, the company has completed the payment of the aforementioned tax and late fees [1] - This matter does not involve any administrative penalties [1]

Group 1 - The company has completed the registration of its overseas investment project in Nigeria, holding a 50% stake in BULLCREST MINERAL RESOURCES LIMITED (BCT), which focuses on lithium and tin mining [1][2] - BCT currently possesses exploration rights for 15 lithium mines and 6 tin mines, along with additional rights through its subsidiaries [1] - The company has received the necessary approvals from the Sichuan Provincial Development and Reform Commission and the Sichuan Provincial Department of Commerce for its overseas investment [2] Group 2 - The overseas investment project is located in Kwara State, Nigeria, with a 50% ownership split between the company and AFRICORP HOLDINGS LIMITED [2] - The company acknowledges potential risks associated with the new operating environment, including cultural, legal, and policy-related challenges, and emphasizes the importance of risk assessment and management [2]

Group 1 - The company, Hebang Biology, announced that it holds a 50% stake in Nigeria's BULLCREST MINERAL RESOURCES LIMITED (BCT) through its wholly-owned subsidiary, Hebang Biology (Hong Kong) Investment Co., Ltd [2] - BCT, established in 2023 under Nigerian federal law, is primarily engaged in the mining, washing, and sales of lithium and tin ores, currently holding 15 lithium and 6 tin mining exploration rights [2] - The company has completed the registration of its overseas investment and received the Overseas Investment Project Filing Notification from the Sichuan Provincial Development and Reform Commission [2]

证券代码：603077 证券简称：和邦生物 公告编号：2025-041 债券代码：113691 债券简称：和邦转债 四川和邦生物科技股份有限公司 关于对外投资项目完成备案登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、项目概述 四川和邦生物科技股份有限公司（以下简称"公司"）通过全资子公司和邦 生物（香港）投资有限公司持有尼日利亚 BULLCREST MINERAL RESOURCES LIMITED （以下简称"BCT"）50%股权。BCT 系一家根据尼日利亚联邦共和国法律成立的 公司，注册号为 7154076，成立时间为 2023 年。BCT 主要从事锂矿、锡矿的开 采、洗选及销售，当前拥有 15 个锂矿和 6 个锡矿探矿权，以及通过控制（BCT 持有 60%的股份）"Deep Earth Mineral Resources Limited"拥有 5 个锂矿探 矿权，"BC Mining Company Limited"拥有 2 个锂矿探矿权。 二、项目备案登记情况 近日，公司已办理完成境外投资的备案登记事 ...

Core Viewpoint - The company has provided guarantees for its subsidiaries, which aligns with its development strategy and financial needs [7][9]. Group 1: Guarantee Details - On July 15, 2025, the company signed a maximum guarantee contract with Shanghai Pudong Development Bank for its subsidiary Sichuan Wujun Photovoltaic Co., Ltd., with a maximum principal amount of RMB 50 million [2][6]. - On August 14, 2025, the company signed a guarantee contract with Bank of Communications for its subsidiary Wujun Chongqing Photovoltaic Co., Ltd., with a maximum principal amount of RMB 80 million [3][6]. Group 2: Internal Decision-Making Process - The company’s board approved the external guarantee authorization for 2025, allowing a total guarantee amount of up to RMB 6 billion, with specific limits based on the subsidiaries' debt ratios [4][8]. Group 3: Financial Overview - As of August 31, 2025, the total external guarantees provided by the company and its subsidiaries amounted to RMB 7.857 billion, representing 42.18% of the company's latest audited net assets [9].

Core Viewpoint - The company, Hebang Biology, announced that as of August 31, 2025, the total external guarantees provided by the company and its subsidiaries amount to 7.857 billion yuan, which represents 42.18% of the company's most recent audited net assets [1] Summary by Categories - **Total Guarantees**: The total external guarantees amount to 7.857 billion yuan, which includes both unused approved guarantee limits and actual guarantees incurred [1] - **Proportion of Net Assets**: The total guarantees represent 42.18% of the company's most recent audited net assets [1] - **Inter-company Guarantees**: The total guarantees provided to wholly-owned and controlling subsidiaries, as well as mutual guarantees among subsidiaries, also amount to 7.857 billion yuan, maintaining the same percentage of 42.18% of net assets [1] - **No Overdue Guarantees**: The company and its subsidiaries do not have any overdue guarantees [1] - **No Guarantees for Related Parties**: The company has not provided guarantees for its controlling shareholders, actual controllers, or their related parties [1]

| 证券代码：603077 | 证券简称：和邦生物 | 公告编号：2025-040 | | --- | --- | --- | | 债券代码：113691 | 债券简称：和邦转债 | | 四川和邦生物科技股份有限公司 关于提供担保的进展公告 2025 年 8 月 14 日，公司与交通银行股份有限公司重庆市分行（以下简称"交 通银行重庆分行"）签订《保证合同》，为公司控股子公司武骏重庆光能有限公司 （以下简称"重庆武骏"）提供担保，保证方式为连带责任保证，公司为重庆武 骏与交通银行重庆分行在 2025 年 8 月 14 日至 2026 年 7 月 22 日期间签订的全部 主合同提供最高额保证担保，担保的主债权本金余额最高额为人民币 8,000.00 万元，保证期间为该笔债务履行期限届满之日起，计至全部主合同项下最后到期 的主债务的债务履行期限届满之日后三年止。本次担保不存在反担保。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | | 四川武骏光能股份有限公司 | | ...